Pomavia 4mg Capsule

Introduction

Pomavia is a prescription medication that contains the active ingredient Pomalidomide. It is available under the brand name Pomavia. This medication is primarily used for the treatment of certain types of cancer, specifically multiple myeloma.

Uses

Pomavia is prescribed to patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. It is used in combination with other medications to help slow down or stop the growth of cancer cells in the body.

Dosage and Administration

The dosage of Pomavia will be determined by your healthcare provider based on your individual condition and response to treatment. Follow the instructions provided by your doctor or pharmacist. Generally, the recommended dose is taken orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal. Swallow the capsule whole with water, without chewing or crushing it.

Mechanism of Action

Pomalidomide, the active ingredient in Pomavia, belongs to a class of medications called immunomodulatory drugs. It works by enhancing the immune system’s ability to attack and destroy cancer cells. Pomalidomide also inhibits the growth of blood vessels that support tumor growth, helping to suppress the progression of multiple myeloma.

Side Effects

Common side effects may include fatigue, nausea, diarrhea, constipation, and decreased appetite. Report any persistent or bothersome side effects to your healthcare provider. Serious side effects may include blood clotting problems, low white blood cell count, or an increased risk of infections. If you experience any of these serious side effects, seek immediate medical attention.

Drug Interactions

Pomavia may interact with other medications, including over-the-counter drugs and herbal supplements. Inform your healthcare provider about all the medications you are currently taking to avoid any potential interactions. Some medications that may interact with Pomavia include warfarin, digoxin, and certain antifungal medications. Discuss with your doctor or pharmacist for more information.

Precautions

Before taking Pomavia, inform your healthcare provider about any existing medical conditions or allergies you may have. This medication may not be suitable for everyone, especially those with severe liver or kidney problems. Follow all the precautions and contraindications provided by your doctor. Pomavia may also interact with other medications or substances, so disclose all the medications you are currently taking.

Storage

Patient Tips

• Take Pomavia exactly as prescribed by your healthcare provider.
• have regular check-ups and laboratory tests to monitor your response to treatment.
• Avoid activities that may increase your risk of bleeding or injury while taking this medication.
• If you miss a dose, take it as soon as you remember. If it is close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule.
• Do not stop taking Pomavia without consulting your healthcare provider, even if you start to feel better.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Imnovid 1 mg hard capsules (Health Professionals SmPC) Available at:
• Pomalidomide (Drugs.com) [Accessed 3 Jun. 2024] (online) Available at:
• pomalidomide capsule (RX) [Accessed 20 Jun. 2024] (online) Available at:
• Pomalidomide (MedlinePlus) [Accessed 26 Jun. 2024] (online) Available at:
• Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5. [Accessed 17 Jun. 2024] Available at: